Related Consortia & Projects
The Alzheimer’s Disease Metabolomics Consortium is a bold initiative funded by the National Institute of Aging that brings together leaders in Alzheimer’s disease clinical and basic research to work in close collaboration with centers of excellence in metabolomics, genetics, biochemistry, engineering and bioinformatics.
The Consortium aims to define metabolic failures across the trajectory of disease connecting peripheral and central changes. We define alterations in biochemical pathways and networks that can help us gain deeper understanding of disease mechanisms and that can highlight novel targets for drug design.
The Alzheimer Gut Microbiome Project is an initiative funded by the National Institute of Aging to investigate the role of the gut microbiome and metabolome in Alzheimer's Disease pathogenesis and in the development of neuropsychiatric symptoms. It brings together 40 scientists from 14 academic institutions to define the role of complex bidirectional interconnections involving the diet, exposome, lifestyle influences, gut microbiome and genome on the metabolome to inform about individuality, vulnerability and unique trajectories of Alzheimer’s disease.
The Mood Disorders Precision Medicine Consortium (MDPMC) is an integrated team of academic researchers dedicated to improving the lives of patients who suffer from major depressive disorder and bipolar disorder. Comprised of leading experts in the fields of genetics, metabolomics, neuroimaging, bioinformatics, and clinical trials, the MDPMC’s mission is to achieve the precision medicine goals of individualizing treatment for mood disorder patients based on an integrated biological understanding of their illnesses and variation in response to treatments.